# A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus

> **NCT01466725** · PHASE2 · TERMINATED · sponsor: **Celgene** · enrollment: 5 (actual)

## Conditions studied

- Discoid Lupus

## Interventions

- **DRUG:** CC-930
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01466725
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-11-01
- **Primary completion:** 2012-07-30
- **Final completion:** 2012-07-30
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The benefit/risk profile does not support continuation of this study.
- **Last updated:** 2019-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01466725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01466725, "A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01466725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*